Skip To Main Content
Ying Chi on Muck Rack

Ying Chi

As seen in: Color Research & Application, Nature, Wiley, MDPI, Virology Journal, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial

|
By Huiyuan Li, Yuan Xu, Yunfei Chen, Lulu Ji, Yanmei Xu, Wenting Zheng, Ting Sun, Rongfeng Fu, Xiaolei Pei, Xiaofan Liu, Feng Xue, Wei Liu, Wentian Wang, Ying Chi, Renchi Yang, Jun S. Wei, Lei Zhang
| Nature Verified
Abstract Autoimmunity remains challenging to treat without broad immunosuppression. We previously showed that anti-CD38 antibody can rapidly elevate platelet counts in refractory immune thrombocytopenia (ITP), but the underlying mechanism was unclear. Here we report that anti-CD38 antibody induces platelet recovery within 3 days, including after retreatment in relapsed cases.
Open in Who Shared Issue with article?

Variant-divergent death: Omicron intensifies bystander T-cell apoptosis via GDF15–BCL2L13

|
By Chao Gao, Hanbing Chen, Ying Chi, Xinxing Lu, Jiahuang Li, Ying Tang, Ruixuan Yu, Nan Shi, Ling Liu, Jianfeng Xie, Haibo Qiu, Jie Chao, Shufeng Li
| Nature Verified
Abstract Severe Omicron cases present profound lymphocytopenia, suggesting variant-specific immune injury. We identify CD63 as a conserved T-cell host factor supporting ACE2-independent SARS-CoV-2 entry. Despite lower intracellular viral loads than the ancestral strain, Omicron elicits enhanced T-cell apoptosis largely through a bystander mechanism.
Open in Who Shared Issue with article?

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity

|
By Wei Liu, Xiaolei Pei, Tenghui Yu, Bingqi Xu, Xinyue Dai, Feng Xue, Lingling Chen, Xiaolin Wang, Yuhua Wang, Yunfei Chen, Xiaofan Liu, Rongfeng Fu, Wentian Wang, Ying Chi, Hui Li, Renchi Yang, Lei Zhang
| Nature Verified
Abstract This prospective phase 1 pilot study evaluated the safety and efficacy of GS001, an adeno-associated virus serotype 8 (AAV8)-based vector encoding B-domain–deleted factor VIII with exploratory assessment of prophylactic immunosuppression. Twelve adult severe hemophilia A participants were enrolled.
Open in Who Shared Issue with article?
See all 11 licensed articles (12 Total)